Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-22
2008-07-22
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S626000, C514S885000
Reexamination Certificate
active
07402601
ABSTRACT:
The use of compound 1 and/or 2 of the formulaeand of physiologically tolerable salts of compound 2 for the treatment of rejection reactions of the organ recipient to the transplanted organ is described.
REFERENCES:
patent: 4061767 (1977-12-01), Ertel et al.
patent: 4087535 (1978-05-01), Heubach
patent: 4284786 (1981-08-01), Kammerer et al.
patent: 4351841 (1982-09-01), Kammerer et al.
patent: 4636513 (1987-01-01), Kammerer et al.
patent: 4965276 (1990-10-01), Bartlett et al.
patent: 5100899 (1992-03-01), Caine
patent: 5268382 (1993-12-01), Bartlett et al.
patent: 5624946 (1997-04-01), Williams
patent: 5688824 (1997-11-01), Williams
patent: 5728721 (1998-03-01), Bartlett
patent: 6133301 (2000-10-01), Bartlett
patent: 6288098 (2001-09-01), Bartlett
patent: 2076555 (1993-02-01), None
patent: 2081173 (1993-04-01), None
patent: 3534440 (1987-04-01), None
patent: 4101324 (1992-07-01), None
patent: 013 376 (1980-07-01), None
patent: 0 217 206 (1987-04-01), None
Dr. Willaim Paul Fundamental Immunology, 1989 2d. Ed., Raven Press NY; Chapter 33 pp. 906-907.
Dwyer et al. Heart, Lung and Circulation 2002, 11, pp. 32-41.
Auchincloss, Jr., “Xenogeneic Transplantations”, Transplantation, 46(1):1-20.
Ivan M. Roitt et al., “Immunology”, ch. 24 “Transplantation and Rejection”, pp. 24.1 to 24.9, Gower Medical Publishing (1985).
K. Ulrichs et al., “Suppression of Natural Xenophile Antibodies with the Novel Immunomodulating Drug Leflunomide,” Transplantation Proceedings, vol. 24, No. 2 (Apr. 1992), pp. 718-719.
C.C.A. Kuchle et al., “Prevention of Kidney and Skin Graft Rejection Rates by Leflunomide, a New Immunolodulating Agent,” Transplantation Proceedings, vol. 23, No. 1 (Feb. 1991), pp. 1083-1086.
D.B.J. Herrmann et al., “Drugs in Autoimmune Diseases,” Klinische Wochenschrift, vol. 68 (Suppl. XXI)(1990), pp. 15-25.
Bartlett et al., “Leflunomide (HWA 486), a novel immunomodulating compund for the treatment of autoimmune disorders and reactions leading to transplantation rejection,” Agents Actions, vol. 32, Nos. ½, 32:10-21 (1991).
Bartlett et al., “Development of Autoimmunity in MRL/lpr Mice and the Effects of Drugs on this Murine Disease,” Scand. J. Rheumatology, S75:290-299 (1988).
Bretzel et al., “Experimental Islet Transplantation in Small Animals,” Pancreatic Islet Cell Transplantation, C. Ricardi, e., R.G. Landis Co., Austin, TX (1992).
Chong et al., “Leflunomide, a Novel Immunomodulatory Agents: In Vitro Analyses of the Mechanism of Immunosuppression,” Transplantation Proceedings, 25:747-749 (1993).
Chong et al., “Leflunomide, a Novel Immunosuppressive Agent,” Transplantation, 55:1361-1366 (1993).
Cosenza et al., “Combination Therapy with Brequinar Sodicum and Cyclosporine Synergistically Prolongs Hamster-to-Rat Cardiac Xenograft Survival,” J. Heart Lung Transplantation, 13:489-497 (1994).
Fontana et al., “Long-Term Follow-Up of Human Islet Autotransplantation,” Transplantation Proceedings, 26:581 (1994).
Foster et al., “Leflunomide Immunosuppression in Rat Small Intestinal Transplantation,” Transplantation Proceedings, 26:1599-1600 (1994).
Glant et al., “Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide,” Immunopharmacology, 23:105-116 (1992).
Hayry et al., “Chronic Allograft Rejection, ” Immunological Reviews, 134:33-81 (1993).
Horak et al., “T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck,” Proc. Natl. Acad. Sci. USA, 88:1996-2000 (1991).
Kahan et al., “Synergistic Interactions of Cyclosporine and Rapamycin to Inhibit Immune Performances of Normal Human peripheral Blood Lymphocytes In Vitro,” Transplantation, 51:232-239 (1991).
Kerckhaert et al., “Effects of Variation in Time and Dose of Cyclophosphamide Injection on Delayed Hypersensitivity and Anibody Formation,” Cellur Immunology, 29:232-237 (1977).
Küchle et al., “Prevention of Kidney and Skin Graft Rejection in Rats by Leflunomide, a New Immunomodulating Agent,” Transplantation Proceedings, 23:1083-1086 (1991).
Mattar et al., “Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide,” FEBS Letters, 334:161-164 (1993).
McChesney et al., “An Evaluation of Leflunomide in the Canine Renal Transplantation Model,” Transplantation, 57:1717-1722 (1994).
Ogawa et al., “Effects of Leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats,” Agents Actions, 31:321-328 (1990).
Ogawa et al., “Therapeutic Effects of Leflunomide, a New Antirheumatic Drug, on Glomerulonephritis Induced by the Antibasement Membrane Antibody in Rats,” Clinical Immunology Immunopathology, 61:103-118 (1991).
Ono et al., “Improved techinque of heart transplantation in rats,” J. Thoracic Cardiovascular Surgery, 57:225-229 (1969).
Popovic et al., “Disease modifying activity of HWA 496 on the development of SLE in MRL/1-mice,” Agents Actions, 19:313-314 (1986).
Schorlemmer et al., “Prolongation of Allogenic Transplanted Skin Grafts and Induction of Tolerance by Leflunomide, a New Immunosuppressive Isoxazol Derivative,” Transplantation Proceedings, 25:763-767 (1993).
Schwartz et al., “Drug-Induced Immunological Tolerance,” Nature, 183:1682-1683 (1959).
Stecher et al., “Disease Modifying Anti-Pheumatic Drugs,” Ann. Report Med. Chem. 18:171-179 (1983).
Stockman et al., “Differential Effects of cyclophosphamide on the B and T Cell Compartments of Adult Mice,” J. Immunology, 110:227-282 (1973).
Thoenes et al., “Leflunomide (HWA 486) Inhibits Experimental Autoimmune Tubulointerstitial Nephritis in Rats,” Int. J. Immunopharmacology, 11:921-929 (1989).
Tiney et al., “Chronic Rejection—An Underfined Conundrum”, Transplantation, 52:389-398 (1991).
Turk et al., “Further Studies on B-Lymphocyte Suppression in Delayed Hypersensitivity, Indicating a Possible Mechanism for Jones-Mote Hypersensitivity,” 24:751-758 (1973).
Williams et al., “Leflunomide Based Immunosuppression in Rat Cardiac and Renal Xenotransplantation,” Presented at Annual Meeting of the Am. Soc. Transplant Surgeons, May 20, 1994, Chicago, IL.
Williams et al., “Leflunomide and Cyclosporic in Rat Cardiac Transplantation”, Presented at Annual Meeting of the Am. Soc. Transplant Surgeons, May 1992, Chicago, IL.
Williams et al., “Leflunomide in Experimental Transplantation,” Transplantation, 57:1223-1231 (1994).
Xiao et al., “Effect of Leflunomide in Control of Acute Rejection in Hamster-to-Rat Cardiac Xenografts,” Transplantation Proceedings, 26:1263-1264 (1994).
Bouwan et al., “Experimental Xenotransplantation in Rodents—I: Skin Versus Heart Grafts,” in Xenotransplantation, Cooper et al., eds. Springer-Verlag, Berlin (1991), pp. 323-329.
Cooper et al., “Introduction,” in Xenotransplanatation, Cooper et al., eds. Springer-Verlag, Berlin (1991), pp. 1-7.
Steinbruchet et al., “Experimental Xenotransplantation in Rodents-Total Lymphoid Irradiation, Cyclosporine, and Monoclonal Antibodies,” Xenotransplantation, Cooper et al., eds. Springer-Verlag, Berlin (1991), pp. 331-338.
Thomas et al., “Immunobiology of Xeonografting in Rodents,” in Xenotransplantation, Cooper et al., eds. Springer-Verlag, Berlin (1991), pp. 139-160.
Van Den Bogaerde et al., “Immunosuppression in Xeonotransplantation,” in Xenotransplantation, Cooper et al, eds. Springer-Verlag, Berlin (1991), pp. 161-178.
Ricordi et al., “Islet Isolation Assessment,” Pancreactic Islet Cell Transplatation, Camillio Ricordi, ed. RG Landis Co., Austin, TX pp. 132-142 (1992).
Williams et al., “Leflu
Arnold Ernst V
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Richter Johann
Sanofi-Aventis Deutschland GmbH
LandOfFree
Pharmaceuticals for the treatment of rejection reactions in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceuticals for the treatment of rejection reactions in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceuticals for the treatment of rejection reactions in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2788458